Rep. Gilbert Ray Cisneros, Jr. Sells Pfizer Inc. (NYSE:PFE) Stock

Representative Gilbert Ray Cisneros, Jr. (D-California) recently sold shares of Pfizer Inc. (NYSE:PFE). In a filing disclosed on January 12th, the Representative disclosed that they had sold between $1,001 and $15,000 in Pfizer stock on December 19th. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Xiaomi (OTCMKTS:XIACF) on 12/30/2025.
• Sold $1,001 – $15,000 in shares of Schneider Electric S.E. (OTCMKTS:SBGSF) on 12/30/2025.
• Sold $1,001 – $15,000 in shares of Hermès International Société en commandite par actions (OTCMKTS:HESAF) on 12/30/2025.
• Purchased $50,001 – $100,000 in shares of Campbell’s (NASDAQ:CPB) on 12/30/2025.
• Sold $1,001 – $15,000 in shares of Tencent (OTC:TCTZF) on 12/30/2025.
• Sold $1,001 – $15,000 in shares of Mitsubishi Heavy Industries (OTCMKTS:MHVYF) on 12/26/2025.
• Sold $1,001 – $15,000 in shares of Bloom Energy (NYSE:BE) on 12/24/2025.
• Sold $1,001 – $15,000 in shares of Arista Networks (NYSE:ANET) on 12/24/2025.
• Sold $1,001 – $15,000 in shares of Coinbase Global (NASDAQ:COIN) on 12/24/2025.
• Sold $1,001 – $15,000 in shares of Chevron (NYSE:CVX) on 12/24/2025.

Pfizer Stock Up 0.8%

Shares of PFE stock traded up $0.22 on Thursday, hitting $25.80. The stock had a trading volume of 25,325,055 shares, compared to its average volume of 44,326,629. The stock has a market cap of $146.66 billion, a price-to-earnings ratio of 15.00 and a beta of 0.47. Pfizer Inc. has a 12-month low of $20.92 and a 12-month high of $27.69. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.28 and a quick ratio of 0.97. The business has a 50 day moving average of $25.31 and a 200 day moving average of $24.98.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.87 earnings per share for the quarter, topping the consensus estimate of $0.79 by $0.08. The company had revenue of $16.65 billion during the quarter, compared to the consensus estimate of $16.94 billion. Pfizer had a return on equity of 20.17% and a net margin of 15.65%.Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. As a group, analysts expect that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, March 6th. Investors of record on Friday, January 23rd will be issued a dividend of $0.43 per share. The ex-dividend date is Friday, January 23rd. This represents a $1.72 annualized dividend and a yield of 6.7%. Pfizer’s dividend payout ratio is 100.00%.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on PFE shares. HSBC reaffirmed a “buy” rating and set a $29.00 price objective on shares of Pfizer in a research report on Wednesday, December 10th. Morgan Stanley reduced their target price on shares of Pfizer from $32.00 to $28.00 and set an “equal weight” rating on the stock in a report on Friday, December 12th. Citigroup assumed coverage on shares of Pfizer in a report on Tuesday, December 2nd. They set a “neutral” rating and a $26.00 price objective for the company. Cowen reissued a “hold” rating on shares of Pfizer in a report on Tuesday, December 30th. Finally, Wolfe Research set a $24.00 target price on Pfizer and gave the stock an “underperform” rating in a report on Wednesday, December 17th. Two research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, thirteen have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $27.88.

Key Stories Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Completion of a key China Phase 3 for migraine drug rimegepant — a successful China trial could speed approvals and expand addressable market for a late‑stage asset. Pfizer Completes Key China Phase 3 Trial for Migraine Drug Rimegepant
• Positive Sentiment: New bioequivalence study for a CGRP migraine asset — early formulation work could support a new, potentially differentiated product presentation if successful. Pfizer Advances CGRP Migraine Asset With New Bioequivalence Study
• Positive Sentiment: Prazosin manufacturing shift with a new bioequivalence study — signals active supply‑chain/cost management and continuity planning that can protect revenues and margins. Pfizer Advances Prazosin Manufacturing Shift With New Bioequivalence Study
• Positive Sentiment: TOFAst real‑world study in ulcerative colitis launched/updated — real‑world evidence can support label expansion, payor discussions and commercial uptake over time. Pfizer’s TOFAst Real-World Study in Ulcerative Colitis: What Investors Should Watch
• Positive Sentiment: CEO pushing for an FDA Priority Review Voucher — management is actively seeking accelerated regulatory paths, which could shorten time‑to‑market for eligible assets. Pfizer CEO Says Company Is Pushing for FDA Priority Review Voucher
• Neutral Sentiment: Bullish valuation piece highlights Pfizer as a value play for 2026 — useful for sentiment but not a company announcement. Pfizer: The Most Intriguing Value Play Of 2026
• Neutral Sentiment: CEO commentary comparing the obesity drug market’s potential to Viagra — signals management optimism about future consumer market opportunities but is speculative. Pfizer CEO plans for soaring consumer market for obesity drugs akin to Viagra
• Neutral Sentiment: Institutional ownership remains high (~66%) — a structural factor that can stabilize share holds but isn’t an immediate catalyst. Pfizer Inc. (NYSE:PFE) is favoured by institutional owners who hold 66% of the company
• Negative Sentiment: Shares and market cap have been under pressure after weak FY 2026 guidance — analysts and investors are debating whether to buy the dip, and guidance remains the primary near‑term headwind. PFE Market Cap Falls More Than $7B in a Month: How to Play the Stock

Hedge Funds Weigh In On Pfizer

Hedge funds have recently added to or reduced their stakes in the business. Capital Advisory Group Advisory Services LLC increased its stake in Pfizer by 2.9% during the second quarter. Capital Advisory Group Advisory Services LLC now owns 13,542 shares of the biopharmaceutical company’s stock worth $328,000 after acquiring an additional 388 shares during the last quarter. Citizens National Bank Trust Department lifted its position in shares of Pfizer by 0.9% during the second quarter. Citizens National Bank Trust Department now owns 46,103 shares of the biopharmaceutical company’s stock worth $1,118,000 after purchasing an additional 395 shares during the last quarter. Peak Asset Management LLC increased its holdings in shares of Pfizer by 1.4% in the 2nd quarter. Peak Asset Management LLC now owns 28,768 shares of the biopharmaceutical company’s stock valued at $697,000 after acquiring an additional 402 shares during the last quarter. Quest Investment Management LLC lifted its holdings in Pfizer by 1.3% in the third quarter. Quest Investment Management LLC now owns 31,768 shares of the biopharmaceutical company’s stock worth $809,000 after acquiring an additional 405 shares during the last quarter. Finally, Community Bank & Trust Waco Texas increased its position in Pfizer by 0.6% in the third quarter. Community Bank & Trust Waco Texas now owns 66,841 shares of the biopharmaceutical company’s stock worth $1,703,000 after buying an additional 412 shares during the period. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.

Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.